The potential anticancer effect of bee venom in combination with sorafenib against HepG2 cell lines via induction of apoptosis and autophagy candidate genes

Egyptian Journal of Medical Human Genetics

Table 1 Gene expression levels of Beclin-1, Bax, Bcl-2 and Bax/Bcl-2 ratio in untreated HepG2 cells, BV-treated cells, Sorf-treated cells and BV/Sorf-treated cells

	Untreated cells	BV-treated cells	Sorf-treated cells	BV/Sorf-treated cells
Beclin-1	1.01 ± 0.09	2.33 ± 0.27^a	1.28 ± 0.15	3.22 ± 0.23^a,b,c
Bax	1.03 ± 0.14	3.60 ± 0.79^a	4.90 ± 0.24^a	6.95 ± 0.09^a,b,c
Bcl-2	1.03 ± 0.16	0.50 ± 0.02^a	0.52 ± 0.04^a	0.12 ± 0.02^a,b,c
Bax/Bcl-2	1.07 ± 0.22	7.24 ± 1.66^a	9.58 ± 0.74^a	63.25 ± 9.69^a,b,c

Samples ran in triplicates in 3 independent experiments. The used treatment concentrations are those of IC₅₀. Data expressed as the mean fold change ± SE
^aSignificantly different from untreated cells at p < 0.05
^bSignificantly different from BV-treated cells at p < 0.05
^cSignificantly different from Sorf-treated cells at p < 0.05